A Randomized, Open-Label, Phase 3 Trial of EPCORITAMAB vs. Investigator?s Choice Chemotherapy In Relapsed/Refractory Diffuse Large B-CELL Lymphoma
Email for information
Research Start Date
The primary objective of the study is to compare the clinical efficacy, safety and tolerability of epcoritamab to investigator's choice of standard of care (SOC) R-GemOx or BR for large B-cell lymphoma.